Previous 10 | Next 10 |
2023-08-22 12:50:11 ET More on psychedelic drug companies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down Psychedelic Stocks: Don't Bet On Just 1 Company Seelos:...
A new study published in the journal “ Frontiers in Psychology ” suggests that psychedelic use and mindfulness meditation may trigger leadership improvements and result in positive leadership outcomes. The preliminary study joins a growing body of scientific literature on the ...
2023-08-14 07:53:07 ET Mind Medicine ( NASDAQ: MNMD ) Monday announced it has entered into a senior secured credit facility with K2 HealthVentures, a healthcare-focused specialty finance company. “This transaction strengthens our balance sheet and provides us with addit...
– Enhances financial flexibility through multiple clinical catalysts on MM-120 and MM-402 product candidates – - The Company’s ending 2Q2023 cash and cash equivalents of $116.9 million and committed credit facility are expected to fund operations into 2026, if cer...
A recent spending bill report from a major Senate committee has acknowledged that federal prohibition is hindering comprehensive research into psychedelics . Sections within the report encourage federally sponsored studies involving psychedelics and marijuana but note that the two drugs’...
2023-08-04 10:57:33 ET Mind Medicine press release ( NASDAQ: MNMD ): Q2 GAAP EPS of -$0.76 misses by $0.21 . As of June 30, 2023, MindMed had cash and cash equivalents totaling $116.9 million compared to $142.1 million as of December 31, 2022. The Company believes ...
2023-08-03 20:52:09 ET Mind Medicine Inc. (MNMD) Q2 2023 Earnings Conference Call August 03, 2023 04:30 PM ET Company Participants Rob Barrow - Chief Executive Officer Schond Greenway - Chief Financial Officer Dan Karlin – Chief Medical Officer Confe...
– Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 with enrollment to be concluded in Q3 2023 – – Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated in Q4 2023 / Q1 2024 – – MM-402 in ASD on track for Phase 1 clinica...
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has entered into a license agreement with Ca...
Psychedelics are all the rage these days thanks to a major surge in psychedelic research and media reporting on hallucinogens. This research has revealed that various psychedelics may have significant mental health benefits, making the substances prime candidates as alternatives for often u...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
2024-07-26 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...
Cluster headaches are headaches characterized by severe pain that often occurs on a side of the head or behind one eye. These headaches may last anywhere between 15 minutes to 3 hours and usually strike suddenly, often recurring more than once a day. The pain experienced by patients is... R...